SecBot SecBot
SECBOTREPLAY Home › Report › FULC

FULC · Fulcrum Therapeutics is being acquired by Slate Medicines in an…

Fulcrum Therapeutics, Inc.; Slate Medicines · PRESS-RELEASE filed Aug 17, 2026 at 07:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Aug 17, 2026 at 07:00 ET

Fulcrum Therapeutics is being acquired by Slate Medicines in an all-stock reverse merger where pre-merger Fulcrum stockholders will own 5% of the combined company (subject to net cash adjustment) and receive an estimated $270M cash dividend immediately before closing. The combined entity will operate as Slate Medicines (ticker SLTE) and focus on Slate's migraine pipeline, including SLTE-1009, backed by a $245M oversubscribed private placement led by Frazier Life Sciences. For Fulcrum stockholders, this is effectively a liquidation event with a large cash dividend and a small ongoing equity stub in a pre-revenue biotech.

  • Pre-merger Fulcrum stockholders to own 5.0% of combined company (subject to net cash adjustment)
  • Fulcrum to pay estimated $270.0M cash dividend to pre-merger stockholders immediately before closing
  • Fulcrum contributes ~$20.3M net cash to combined entity
  • Slate secured $245M oversubscribed private placement led by Frazier Life Sciences

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access